Allianz Asset Management GmbH Grows Position in Pediatrix Medical Group, Inc. $MD

Allianz Asset Management GmbH increased its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 158.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 158,777 shares of the company’s stock after purchasing an additional 97,365 shares during the quarter. Allianz Asset Management GmbH owned 0.18% of Pediatrix Medical Group worth $2,660,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of MD. Ameriprise Financial Inc. grew its position in shares of Pediatrix Medical Group by 175.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 744,473 shares of the company’s stock valued at $10,683,000 after acquiring an additional 474,186 shares during the period. American Century Companies Inc. raised its position in Pediatrix Medical Group by 28.6% during the second quarter. American Century Companies Inc. now owns 1,931,867 shares of the company’s stock worth $27,722,000 after acquiring an additional 430,029 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Pediatrix Medical Group by 669.4% during the second quarter. BNP Paribas Financial Markets now owns 476,098 shares of the company’s stock worth $6,832,000 after purchasing an additional 414,216 shares in the last quarter. Hillsdale Investment Management Inc. lifted its stake in Pediatrix Medical Group by 75,200.0% in the 2nd quarter. Hillsdale Investment Management Inc. now owns 376,500 shares of the company’s stock valued at $5,403,000 after buying an additional 376,000 shares in the last quarter. Finally, Brandywine Global Investment Management LLC acquired a new position in shares of Pediatrix Medical Group during the second quarter valued at approximately $5,310,000. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Pediatrix Medical Group

In related news, Director Michael A. Rucker sold 10,478 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $23.00, for a total transaction of $240,994.00. Following the completion of the transaction, the director owned 59,101 shares of the company’s stock, valued at approximately $1,359,323. This represents a 15.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Mark S. Ordan sold 23,000 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $22.41, for a total transaction of $515,430.00. Following the transaction, the chief executive officer directly owned 302,805 shares in the company, valued at approximately $6,785,860.05. This represents a 7.06% decrease in their position. The SEC filing for this sale provides additional information. 0.90% of the stock is owned by company insiders.

Pediatrix Medical Group Stock Performance

Shares of MD stock opened at $21.50 on Thursday. The stock’s 50-day moving average price is $21.72 and its 200 day moving average price is $19.19. The company has a quick ratio of 1.83, a current ratio of 1.83 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $1.85 billion, a PE ratio of 11.32 and a beta of 0.76. Pediatrix Medical Group, Inc. has a 52-week low of $11.84 and a 52-week high of $24.99.

Analyst Ratings Changes

Several brokerages have issued reports on MD. UBS Group upped their target price on Pediatrix Medical Group from $16.50 to $23.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Monday, December 29th. Zacks Research downgraded shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a report on Friday, January 23rd. Finally, Truist Financial upped their price objective on Pediatrix Medical Group from $17.00 to $24.00 and gave the company a “hold” rating in a report on Monday, November 10th. One equities research analyst has rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $21.00.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.